This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Tyrosine Kinase Inhibitors (TKI) Events & Webinars | PP-PF-ONC-GB-0412, February 2024

Oncology
New horizons in the management of advanced colorectal cancer
Stivarga® (regorafenib)
PP-STI-GB-0417, February 2025
Expert Perspectives in CRC - video series 1 (UKOF)
Stivarga® (regorafenib)
PP-STI-GB-0398, July 2024
Expert Perspectives in CRC - video series 2 (ESMO-GI)
Stivarga® (regorafenib)
PP-STI-GB-0399, July 2024
Expert Perspectives in CRC - video series 3
Stivarga® (regorafenib)
PP-STI-GB-0410, August 2024
Empowering Nurses for Colorectal Cancer Care
Stivarga® (regorafenib)
PP-STI-GB-0396, July 2024
Empowering Nurses for Colorectal Cancer Care - Part 2
Stivarga® (regorafenib)
PP-STI-GB-0367, July 2024
Frontiers at St Mark’s 2023
Stivarga® (regorafenib)
PP-STI-GB-0397, July 2024
UKOF 2023 Symposium
Stivarga® (regorafenib)
PP-STI-GB-0274, February 2024
Ask the experts: Three key questions on mCRC
Stivarga® (regorafenib)
PP-STI-GB-0205, February 2024
The treatment landscape in mCRC
Stivarga® (regorafenib)
PP-STI-GB-0202, February 2024
Bayer Oncology HCC Clinical Expert Series
Nexavar® (sorafenib) | Stivarga® (regorafenib)
The management and treatment of patients
Nexavar® (sorafenib) | Stivarga® (regorafenib)
Expert opinion
Stivarga® (regorafenib)
PP-STI-GB-0200, February 2024